Secretome Therapeutics Secures Venture Funding to Advance Duchenne Cardiomyopathy Cell Therapy

According to a recent LinkedIn post from Secretome Therapeutics, the company has received $250,000 in funding from Parent Project Muscular Dystrophy (PPMD) through the PPMD Venture Pathways program. The post indicates that the funding is intended to advance STM-01, Secretome’s neonatal cardiac progenitor cell therapy candidate, for Duchenne-associated cardiomyopathy.

The LinkedIn post suggests that this external, disease-focused capital may help de-risk early development efforts around STM-01 and could validate investor interest in novel cardiac approaches for Duchenne muscular dystrophy. While the amount is modest in absolute terms, such backing from a specialized nonprofit may enhance Secretome Therapeutics’ visibility in the rare disease and cell therapy ecosystem and potentially support future partnering or financing discussions.

As described in the post, the support also underscores the strategic focus on cardiac manifestations of Duchenne, an area of significant unmet need that could offer a differentiated niche within the broader neuromuscular and rare disease markets. For investors, continued progress of STM-01, coupled with advocacy-group partnerships like PPMD’s, may be an indicator of Secretome Therapeutics’ ability to access non-dilutive funding and to align its pipeline with stakeholder priorities.